Glen Mills, PA, United States of America

Klare Lazor Bersch

This inventor holds 3 USPTO granted patents and 4 published patent applications. Top assignees: Prelude Therapeutics Incorporated, Prelude Therapeutis Incorporated. Active years: 2023-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Klare Lazor Bersch. Retrieved from https://idiyas.com/inventor/klare-lazor-bersch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

Average Co-Inventor Count = 6.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Journey of Klare Lazor Bersch

Introduction: Klare Lazor Bersch, a pioneering inventor hailing from Wilmington, DE, has made significant contributions to the world of technology and innovation.

Latest Patents: Klare Lazor Bersch's latest patents focus on advancements in renewable energy technologies, sustainable materials, and cutting-edge medical devices.

Career Highlights: With a career spanning over two decades, Klare Lazor Bersch has been at the forefront of groundbreaking inventions, holding numerous patents in various fields such as biotechnology, nanotechnology, and artificial intelligence.

Collaborations: Throughout her career, Klare Lazor Bersch has collaborated with leading research institutions, universities, and innovative companies to bring her ideas to life and make a lasting impact on society.

Conclusion: Klare Lazor Bersch's relentless passion for innovation and her dedication to pushing the boundaries of what is possible have solidified her reputation as a trailblazing inventor in the ever-evolving world of technology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…